Key Highlights

● DaVita fell sharply on a day when health care was the best-performing S&P 500 sector.

● Earnings per share beat consensus by $0.27, and Revenue also topped forecasts.

● The company's outlook disappointed, overshadowing the quarterly beat.

● Eli Lilly closed at a record $1,373.70 after raising its 2026 revenue guidance.

DaVita (NYSE:DVA) topped estimates on both the top and bottom lines, yet a disappointing outlook sent the kidney-care company sharply lower on a day when health care led the market.

Swimming against the tide

On a day when health care was the best-performing sector in the S&P 500, DaVita went the other way. Shares tumbled, according to market reports, after the kidney-care provider paired a quarterly beat with an outlook that left investors disappointed. The exact timing of the measured move was not clear in the report, but the direction was unmistakable.

DaVita is one of the largest providers of dialysis services in the United States, operating clinics that treat patients with chronic kidney disease and kidney failure. Its earnings depend heavily on patient volumes, the mix between government and commercial insurance, and the cost of running its centres.

The beat

The quarter itself was better than expected. Earnings Per Share came in $0.27 above consensus, according to market reports, and revenue also topped forecasts. Ordinarily, a beat on both lines would be a good day for a stock.

The outlook

The problem was what came next. DaVita's outlook disappointed investors, according to market reports. In health care services, guidance often matters more than the quarter just reported, because it tells investors how management expects volumes, pricing and costs to evolve. When the forward view falls short of hopes, a strong quarter can be quickly forgotten.

That pattern repeated across the market on Thursday. Baxter (NYSE:BAX) fell in premarket trading despite a third-quarter beat, and Stryker (NYSE:SYK) slid in after-hours trading after a revenue miss and guidance below consensus. The lesson for many companies this earnings season has been that a beat is not enough without a convincing outlook.

A strong day for health care, almost everywhere else

DaVita's decline stood out because the sector around it was surging. Health care finished as the best S&P 500 sector, led by Eli Lilly (NYSE:LLY), which rose to a record close of $1,373.70 after raising its 2026 revenue guidance, and Merck (NYSE:MRK), which beat and raised its profit outlook. HCA Healthcare (NYSE:HCA), a hospital operator, also rose after beating estimates. The pharma ETF IHE climbed at midday.

One report said investors rotated into health care, financials and real estate, which helped limit losses in the major indexes. Against that backdrop, DaVita's slide appeared tied to its own outlook rather than any broad aversion to health care stocks.

The broader market

The S&P 500 slipped 23.59 points to 7,720.39, its first decline in four sessions, largely because of a historic plunge in Alphabet (NASDAQ:GOOGL), which suffered its worst day since its 2004 IPO. More than 400 S&P 500 members still rose, and eight of 11 sectors advanced.

The Dow lost 132.54 points to 52,342.56, the Nasdaq Composite fell 365.13 points to 26,184.72, and the Russell 2000 gained 28.71 points to 2,859.22. One market strategist said, "Money is rotating within the market rather than leaving it."

The economic data offered a strong backdrop. Third-quarter GDP accelerated from the second quarter and beat forecasts, while September PCE Inflation ran hot, keeping pressure on the Federal Reserve.

What to watch

For DaVita, the key question is whether the outlook reflects temporary pressures or something more lasting. Investors will listen for any detail on treatment volumes and cost trends in management's commentary and future updates.

More broadly, health care earnings continue in the coming days. Friday's Employment Cost index matters for a labour-intensive Business like dialysis, where staffing costs are significant. The Federal Reserve's December 8–9 meeting, where futures lean toward a rate hike, will also shape the backdrop for health care stocks.